Antibody Drug Conjugate Research Solutions

Antibody-Drug Conjugates (ADCs) couple the precise targeting ability of monoclonal antibodies and the powerful effects of small-molecule cytotoxic drugs. This strategy enhances the precision of cancer treatments while reducing the unwanted side effects commonly seen with traditional therapies. Using high-quality Antibodies and reagents, enhances the outcome of your research immensely.

OriGene's Solution for ADC Research

Explore our options and find the right solution for
your research. 

Antibody Drug Conjugates Mechanism

Payloads and Linker

Detecting payloads and linkers is important as it ensures the stability, efficacy, and safety of the therapeutic compound.
These components need to be tracked to verify the successful delivery and release of the payload at the target cell.

Targets for Antibodies Against Payloads 

Bring your research to the next level with OriGene’s available antibodies against mulitple payloads. 

ELISA Application Reference Data

ELISA DME101003-MMAE Figure 1

Elisa assay graph

ELISA analysis using anti-MMAE antibody and IgG-MMAE molecule. The EC50 is 1.356 ng/ml.

ELISA plates were pre-coated with IgG-Dxd (0.2μg/per well). Serial diluted anti-Dxd monoclonal antibody (TA421202) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for anti-Dxd monoclonal antibody binding with IgG-Dxd is 3.690ng/ml

Antibodies Against Linker - Target 

Explore OriGene’s monoclonal Anti-CL2A antibody against linker and enhance your research.

ELISA Application Reference Data

ELISA plates were pre-coated with IgG-CL2A (0.2μg/per well). Serial diluted anti-CL2A monoclonal antibody (TA421198) solutions were added, washed, and incubated with secondary antibody before ELISA reading. From above data, the EC50 for anti-CL2A monoclonal antibody binding with IgG-CL2A is 12.57ng/ml.

ADC Internalization Labeling Reagents

The ADC internalization labeling reagents are essential tools for advancing your ADC research. Specifically designed for precision. Further, pH sensitive internalization reagents ensure that the reagents can effectively enter the target cells and release the drug payload at the desired intracellular pH. This specificity enhances the efficacy of the ADC's by minimizing offtarget effects and improving overall results.

Enhance your ADC development process with OriGene's comprehensive internalization labeling reagents for specific and reliable research results.

Reagent Type Product Number
ADC internalization pH sensitive IgG labeling reagent
ADC internalization pH sensitive IgG labeling reagent plus
ADC Internalization MMAE IgG labeling reagent

Antibody Drug Conjugates Internalization

Specific Internalization of GPRC5D ADC BMK-AR100090 Conjugate in GPRC5D-Positive Cells (K562-GPRC5D Stable Expression Cell Line, Right), with No Detection in K562 Cells Lacking GPRC5D Overexpression (Left).

Biosimilar Antibodies in ADC Research

Biosimilar antibodies are revolutionizing the field of Antibody-Drug Conjugate (ADC) research, providing a cost-effective and highly reliable alternative to innovator biologics. These biosimilars deliver comparable efficacy, safety, and quality to reference monoclonal antibodies, making them an invaluable resource for researchers aiming to develop next-generation ADC therapeutics. With their affordability and consistent performance, biosimilar antibodies are driving innovation in ADC development, accelerating drug discovery, and enhancing accessibility for pharaceutical research teams.

Why Choose Biosimilar Antibodies for ADC Research?

  • Cost-Effective Solutions
  • Consistent and Reliable Performance
  • Accelerated Research Timelines

Selection of OriGene’s Biosimilars:

  • Atezolizumab
  • Gemtuzumab Ozogamicin
  • Praluzatamab
  • Magrolimab

Illustration of antibodies used in antibody drug conjugate research, highlighting their role in targeting tumors, while not attacking healthy cells.

Explore of our biosimilars by visiting https://www.origene.com/research-areas/biosimilars